Genomic DNA at sequence-selective motifs (gDNA)

Genomic DNA at sequence-selective motifs refers to specific nucleotide sequences within the genome that serve as binding sites for small molecules, often targeting the minor or major grooves of the double helix. Unlike non-specific DNA intercalators, these agents recognize particular base-pair sequences, such as AT-rich regions or specific G-C patterns, allowing for more targeted modulation of genomic function (Dervan & Edelson, 2003, PMID: 12870889). This targeting strategy is primarily utilized to interfere with the binding of transcription factors to promoter or enhancer regions, thereby regulating the expression of specific genes associated with disease (Waring, 1981, PMID: 7017412). In oncology, drugs like trabectedin bind to the minor groove at specific triplets, disrupting the DNA repair machinery and transcriptional regulation in cancer cells (D'Incalci & Galmarini, 2010, PMID: 20570471). Additionally, sequence-selective alkylating agents like pyrrolobenzodiazepines (PBDs) form covalent adducts at specific sites, leading to potent cytotoxicity (Mantaj et al., 2017, PMID: 28110108). While promising for precision medicine, the primary challenge remains achieving sufficient specificity to avoid widespread genotoxicity and off-target effects in healthy tissues.

Other names

Sequence-specific DNAMinor groove DNAMajor groove DNADNA motifsDeoxyribonucleic acid

Drugs targeting sequence-selective motifs typically interact via minor groove binding, intercalation, or covalent adduct formation at specific nucleotide sequences. These interactions physically block the access of transcription factors, polymerases, and other DNA-binding proteins to their cognate sites, thereby inhibiting gene expression, DNA replication, or inducing site-specific DNA damage and apoptosis (D'Incalci & Galmarini, 2010, PMID: 20570471; Mantaj et al., 2017, PMID: 28110108).